This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer's Mad Dash: QCOR MNK

NEW YORK (TheStreet) -- Jim Cramer took a long look at the $5.6 billion buyout of Questcor Pharmaceuticals (QCOR) by Mallinckrodt Pharmaceuticals (MNK - Get Report) on CNBC's "Cramer's Mad Dash" segment Tuesday.

Both stocks shot higher on Monday's announcement, said TheStreet's Cramer, co-manager of the Action Alerts PLUS portfolio.  However, it didn't take long for Mallinckrodt shares to start falling to almost $55 by noon on Monday. Eventually the stock closed near $61. Shares are now up slightly to $62.

"People hate this deal," Cramer said. Questcor is under investigation by the Department of Justice for its promotional practices. It is seen as a one-product company, making it difficult for Mallinckrodt investors to understand why the need to make this acquisition, he added. 

Cramer spoke with Mark Trudeau, president and CEO of Mallinckrodt, on Monday's Mad Money and the executive argued Questcor is a great acquisition. Cramer said Trudeau made clear his company did its due diligence on Questcor regarding its promotional practices, and everything checks out just fine. 

During the program Cramer said that with this deal Mallinckrodt is "incredibly inexpensive."

Must Read: Why World Wrestling Entertainment Got Beat Down Today: StockTwits.com

Tuesday, however, he noted only that "people do not trust this deal."


-- Written by Bret Kenwell in Petoskey, Mich.

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
MNK $122.73 -0.92%
QCOR $93.60 1.65%
AAPL $122.99 -0.32%
FB $96.99 1.78%
GOOG $631.93 0.63%

Markets

Chart of I:DJI
DOW 17,751.39 +121.12 0.69%
S&P 500 2,108.57 +15.32 0.73%
NASDAQ 5,111.7330 +22.5270 0.44%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs